Mode
Text Size
Log in / Sign up

Genetic variants in OSTN and common haplotypes are associated with increased residual pulmonary vascular obstructionGenetic factors and proteins linked to lung blockage after blood clots

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that specific genetic loci like OSTN and common haplotypes are associated with increased risk of RPVO.

This meta-analysis evaluated genetic variants and plasma metabolites associated with residual pulmonary vascular obstruction (RPVO) and recurrence in patients with unprovoked pulmonary embolism. The analysis included 586 participants for the meta-GWAS and 1,617 for the recurrence analysis.

Key findings include a ~2-fold increase of RPVO associated with the OSTN locus (rs59109356) and a ~3-fold increase of RPVO associated with a common haplotype (AHSG/HRG/KNG1). Additionally, the CCN4 locus showed evidence of association approaching genome-wide significance for RPVO. Conversely, the IL1RAP locus was associated with a 28% reduction in RPVO. Mendelian Randomization suggested a link between IL1RAP and RPVO, while both the CCN4 and IL1RAP loci showed statistical evidence of association with pulmonary embolism recurrence (p=0.06 and p=0.02, respectively).

The authors suggest these findings indicate that inflammation is a key mechanism underlying RPVO rather than impaired fibrinolysis. However, the clinical application of these genetic markers for individual patient management is not yet established. The results provide a basis for further research into inflammatory pathways in pulmonary embolism.

When someone suffers from an unprovoked pulmonary embolism, a blood clot blocks a lung artery. Sometimes, even after treatment, some of that blockage remains. This is called residual pulmonary vascular obstruction. Understanding why this happens is vital for managing long-term lung health.

Researchers looked at genetic variants and proteins in the blood to see what influences these lasting blockages. They found that certain genetic spots, like the OSTN and a common haplotype involving AHSG, were linked to a significant increase in remaining blockages. In contrast, a specific gene called IL1RAP was associated with a 28% reduction in these obstructions.

These findings suggest that inflammation plays a major role in why some blockages persist rather than just the body's ability to dissolve clots. While these results help pinpoint the biological mechanisms at play, they are based on genetic associations and protein levels. Talk to your doctor to understand how these specific markers might relate to your personal health.

What this means for you:
Specific genetic markers and proteins may influence how much a blood clot continues to block lung vessels.

Common questions

What is residual pulmonary vascular obstruction?

This refers to blood vessel blockages in the lungs that remain after a patient has had a pulmonary embolism. The study looked at how genetics and proteins influence whether these blockages stay or go away.

Which genetic factors were linked to more lung blockage?

The study found that the OSTN locus was associated with about a 2-fold increase in remaining blockages. Additionally, a common haplotype involving AHSG, HRG, and KNG1 was associated with a 3-fold increase in these obstructions.

Is there anything that helps reduce the blockage?

The study found that the IL1RAP gene, which relates to certain protein levels in the blood, was associated with a 28% reduction in residual pulmonary vascular obstruction. This suggests inflammation may be a key factor.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Background and Aims: Residual pulmonary vascular obstruction (RPVO) defined as the persistence of thrombotic material within the pulmonary arteries several months after an acute pulmonary embolism (PE) is associated with an increased risk of severe complications, including recurrent events and chronic pulmonary hypertension. However, the genomic architecture underlying RPVO in unprovoked PE remains poorly understood, and this study aims to address this gap. Method: By leveraging genetic and imaging RPVO data from three independent cohorts totaling 586 unprovoked PE patients, we conducted a meta-analysis of genome wide association study (GWAS) of RPVO using a dedicated statistical method to handle the semi-continuous distribution of RPVO. The meta-GWAS was complemented by haplotype association analyses and transcriptome wide association studies as well as Mendelian Randomization (MR) approaches based on plasma metabolites and proteins. Results: Through meta-GWAS, we identified one locus, OSTN, associated with RPVO (lead variant rs59109356 associated with a ~2-fold increase of RPVO, p=3.92x10-8). A second locus, CCN4, previously reported to associate with pulmonary fibrosis, was also identified, with evidence of association approaching genome-wide significance (p=6.7x10-8). We also identified a common haplotype spanning over AHSG/HRG/KNG1 associated with a ~3-fold increase of RPVO (p=2.96x10-8). Using plasma protein-based MR, we demonstrated that one unit increase in genetically determined plasma levels of IL-1 R AcP encoding IL1RAP was associated with a 28% (p=1.32x10-6) reduction in RPVO. We also observed statistical evidence that the CCN4 (p=0.06) and IL1RAP (p=0.02) loci associate with the risk of PE recurrence in a sample of 1,617 unprovoked PE patients. Conclusions: By identifying novel molecular determinants of RPVO that map to loci involved in inflammatory pathways and vascular remodeling, our study provides evidence that inflammation is the predominant, and likely the key mechanism underlying RPVO, whereas impaired fibrinolysis appears to play a more limited role.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.